partnershipIf NCI is willing to fund clinical trials why does ONC need a pharma parter. Could ONC arrange to liscence reolysin to pharmas once trials are completed under a liscencing arrangement whereby ONC would pay say 20% to a pharma to distribute reolysin and keep 80% for itself.
The income under a liscencing arrangment could easily fund further trials and legal costs to protect the patents from infringment.
I do not know if the above is a realistic possibility and would like to receive comment.
Since the management of ONC own very few shares, (I think Brad owns only 8000 shares, although he as options) this scenario would seem to fit what I understand is Brad's intention of obtaining the greatest possible return for ONC